PD-L1 Antibody

4059-002mg ProSci 0.02 mg 206.18 EUR
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

PD-L1 Antibody

4059-01mg ProSci 0.1 mg 523.7 EUR
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

PD-L1 Antibody

P1013-01m SAB 0.1m 224.4 EUR

PD-L1 Antibody

P1013-1ml SAB 1ml 807.6 EUR

PD-L1 Antibody

R31573 NSJ Bioreagents 100 ug 419 EUR

PD-L1 Antibody

R33263-100UG NSJ Bioreagents 100 ug 399 EUR

Anti-PD-L1 Antibody

A1454-100 Biovision 405.6 EUR

Anti-PD-L1 Antibody

A1454-30T Biovision 175.2 EUR

Mouse PD-L1 Antibody

32903-05111 AssayPro 150 ug 313.2 EUR

PD-L1 Conjugated Antibody

C49251 SAB 100ul 476.4 EUR

PD-L1 Antibody [F6A9]

SD8639-002mg ProSci 0.02 mg 253.22 EUR
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

PD-L1 Antibody [F6A9]

SD8639-01mg ProSci 0.1 mg 723.62 EUR
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

PD-L1 Antibody [F2G2]

SD8641-002mg ProSci 0.02 mg 253.22 EUR
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

PD-L1 Antibody [F2G2]

SD8641-01mg ProSci 0.1 mg 723.62 EUR
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

Anti-PD-L1 antibody

STJ130022 St John's Laboratory 50 µl 385.2 EUR
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Anti-PD-L1 antibody

STJ130023 St John's Laboratory 50 µl 385.2 EUR
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Anti-PD-L1 antibody

STJ130024 St John's Laboratory 50 µl 385.2 EUR
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Anti-PD-L1 antibody

STJ180217 St John's Laboratory 0.1 ml 336 EUR

Anti-PD-L1 antibody

STJ180383 St John's Laboratory 0.1 ml 295.2 EUR

Anti-PD-L1 antibody

STJ190082 St John's Laboratory 200 µl 236.4 EUR
Description: Unconjugated Mouse monoclonal to PD-L1 (AS1A7)

PD-L1 Peptide

46-156P ProSci 0.1 mg 405.6 EUR
Description: CD274 / PD-L1 Peptide

PD-L1 Peptide

4059P ProSci 0.05 mg 197.7 EUR
Description: (IN) PD-L1 peptide

PD-L1 Protein

20-abx263458 Abbexa
  • 1930.80 EUR
  • 393.60 EUR
  • 276.00 EUR
  • 100 ug
  • 10 ug
  • 2 µg

PD-L1 Protein

20-abx261703 Abbexa
  • 4101.60 EUR
  • 393.60 EUR
  • 276.00 EUR
  • 1 mg
  • 20 ug
  • 5 ug

Anti-PD-L1

DB-241-0.1 DB Biotech 100 μl 469.2 EUR
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1

DB-241-0.2 DB Biotech 200 μl 675.6 EUR
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1

DB-241-0.5 DB Biotech 500 μl 889.2 EUR
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1

DB-241-1 DB Biotech 1 ml 1450.8 EUR
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1

DB-241-RTU-15 DB Biotech 15 ml 813.6 EUR
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Anti-PD-L1

DB-241-RTU-7 DB Biotech 7 ml 519.6 EUR
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Anti-PD-L1

DB241-RTU-15 DB Biotech 15 ml 813.6 EUR
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Anti-PD-L1

DB241-RTU-7 DB Biotech 7 ml 519.6 EUR
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

PD-L1, CD274

E6TA00108 EnoGene 0.1mg 411.6 EUR

PD-1/PD-L1 inhibitor 2

B6023-25 ApexBio 25 mg 525.6 EUR
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor.

PD-1/PD-L1 inhibitor 2

B6023-5 ApexBio 5 mg 205.2 EUR
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor.

PD-1/PD-L1 inhibitor 1

B6172-25 ApexBio 25 mg 543.6 EUR
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems.

PD-1/PD-L1 inhibitor 1

B6172-5 ApexBio 5 mg 201.6 EUR
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems.

PD-1/PD-L1 Inhibitor 2

B1050-25 Biovision 679.2 EUR

PD-1/PD-L1 Inhibitor 2

B1050-5 Biovision 242.4 EUR

PD-1/PD-L1 Inhibitor 1

B1213-25 Biovision 679.2 EUR

Anti-PD-L1 Antibody (IHC411)

A1549-50 Biovision 222 EUR

Anti-PD-L1/CD274 antibody

PAab06280 Lifescience Market 100 ug 426 EUR

anti- PD-L1/CD274 antibody

FNab06280 FN Test 100µg 606.3 EUR
Description: Antibody raised against PD-L1/CD274

anti- PD-L1/CD274 antibody

FNab06281 FN Test 100µg 658.5 EUR
Description: Antibody raised against PD-L1/CD274

Anti-PD-L1/CD274 Antibody

PA1851 BosterBio 100ug/vial 352.8 EUR

Anti-PD-L1/CD274 Antibody

PB9154 BosterBio 100ug/vial 352.8 EUR

Anti-PD-L1/CD274 Antibody

PB9994 BosterBio 100ug/vial 352.8 EUR

Anti-CD274 / PD-L1 antibody

STJ70646 St John's Laboratory 100 µg 430.8 EUR

Ribosome-inactivating protein PD-L1 / PD-L2 Antibody

20-abx319445 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ribosome-inactivating protein PD-L1/PD-L2 Antibody

1-CSB-PA306294LA01PJJ Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Unconjugated. Tested in the following application: ELISA

PD-L1 Rabbit pAb

A11273-100ul Abclonal 100 ul 369.6 EUR

PD-L1 Rabbit pAb

A11273-200ul Abclonal 200 ul 550.8 EUR

PD-L1 Rabbit pAb

A11273-20ul Abclonal 20 ul 219.6 EUR

PD-L1 Rabbit pAb

A11273-50ul Abclonal 50 ul 267.6 EUR

PD-L1 Recombinant Protein

91-293 ProSci 0.05 mg 405.6 EUR
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.